Comparison of Two Different Pulsed Radiofrequency Modes for Prevention of Postherpetic Neuralgia in Elderly Patients with Acute/Subacute Trigeminal Herpes Zoster

Cheng-Fu Wan, MD; Tao Song, MD

ABSTRACT

Objective: Trigeminal postherpetic neuralgia (PHN) is often refractory to treatment. Pulsed radiofrequency (PRF) neuromodulation can help in preventing PHN after herpes zoster. This study aimed to compare the efficacy and safety of two different PRF modes on gasserian ganglion neuromodulation in elderly patients with acute/subacute trigeminal herpes zoster.

Materials and Methods: A total of 120 elderly patients with acute or subacute (within past three months) trigeminal herpes zoster were randomized to receive either a single cycle of high-voltage, long-duration PRF (HL-PRF group; N = 60) or three cycles of standard PRF (S-PRF group; N = 60). Patients were followed up for six months after treatment. Visual analog scale (VAS) pain score, 36-Item Short Form Health Survey (SF-36) score, and pregabalin at baseline and at different time points during follow-up were recorded.

Results: VAS and SF-36 scores declined significantly from baseline levels in both groups (p < 0.001). The scores were significantly lower in the HL-PRF group than in the S-PRF group at some time points (p < 0.05). The mean dose of pregabalin was significantly lower in the HL-PRF group than in the S-PRF group on days 3, 14, and 28 after treatment (p < 0.05). No serious adverse events occurred in either group.

Conclusion: HL-PRF neuromodulation of the gasserian ganglion appears to be more effective than S-PRF for preventing PHN in the elderly.

Clinical Trial Registration: ChiCTR2000038775.

Keywords: 36-Item Short Form Health Survey, pulsed radiofrequency, trigeminal herpes zoster, visual analog scale

Conflict of Interest: The authors declare that they have no conflict of interests.

INTRODUCTION

Postherpetic neuralgia (PHN) is the most common complication following herpes zoster. It presents as a persistent or paroxysmal stabbing or burning pain, usually beginning ≥3 months after complete healing of the skin lesions (1-3). It is often refractory to pharmacological treatment (4–7). The risk factors for PHN include older age, severe acute pain, severe rash, and immunocompromised state (8,9). Trigeminal herpes zoster is more likely to convert to PHN and cause more severe pain than herpes zoster of spinal nerves (10–12), and so every effort must be made to prevent the transition from acute trigeminal herpes zoster to trigeminal PHN, especially in the elderly (12,13).

Pulsed radiofrequency (PRF) neuromodulation is an advanced non-neurodestructive method (13,14) for relief of neuralgic pain. Several previous studies have demonstrated that standard-mode PRF is effective in controlling PHN (15–17). Our own research found that high-voltage, long-duration PRF (HL-PRF) is also effective and safe (18,19), but it is not known whether it is more effective than the standard mode. This study aimed to determine which of the two modes is more effective for preventing PHN in elderly patients with acute/subacute trigeminal herpes zoster.

MATERIALS AND METHODS

Study Design and Setting

This randomized controlled clinical trial was conducted from February 14, 2019, to March 31, 2020, at the First Affiliated Hospital of China Medical University, Shenyang, China.

Address correspondence to: Tao Song, MD, Department of Pain Medicine, the First Affiliated Hospital to China Medical University, Shenyang, China. Email: songtaocmu@163.com

Department of Pain Medicine, the First Affiliated Hospital to China Medical University, Shenyang, China

For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please go to http://www.wiley.com/WileyCDA/Section/id-301854.html

Source(s) of financial support: This study was supported by the Foundation of Liaoning Province Education Department (grant number QNZR20200007).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Patients
Inclusion Criteria
1) Age ≥65 years; 2) history of trigeminal herpes zoster within the last three months; 3) persistent intense pain, with local skin hyperalgesia, numbness, or sensory abnormalities even after complete healing of skin lesions; 4) pain not controlled with standard pharmacotherapy (antiepileptic drugs, antidepressants, opioids) or physical treatments as recommended by the International Association for the Study of Pain (20); and 5) 24-hour visual analog scale (VAS) pain score ≥5.

Exclusion Criteria
1) Severe coagulation disorder or current anticoagulant treatment; 2) severe liver or kidney dysfunction; 3) severe cardiopulmonary disease; 4) history of drug abuse; or 5) intellectual inability to complete self-evaluation by VAS or 36-Item Short Form Health Survey (SF-36).

Randomization and Sequence Generation
Out of the 157 patients who were screened, we excluded 37 patients (19 patients because they did not meet the inclusion criteria, 10 patients because they declined to participate, and 8 patients because of other reasons). The remaining 120 patients were randomly assigned (1:1) to receive either HL-PRF group (N = 60) or standard PRF (S-PRF group; N = 60). Figure 1 shows the patient selection and randomization process. The randomization was centrally controlled by the Human Ethics Committee (China Medical University, Shenyang, China) to ensure allocation concealment. An independent statistician used computer-generated randomization sequences to assign patients in blocks of two and four, stratified by site.

This study followed the ethical principles of the Declaration of Helsinki, and the study protocol was approved by the Human Ethics Committee of the First Affiliated Hospital of China Medical University (No. 2018-308). Informed consent forms were signed by all patients. This trial was registered with chictr.org.cn (No. ChiCTR2000038775).

Description of PRF
Treatment was administered with the patient in the supine position, with 2 L/min of oxygen supplied through a nasal catheter and continuous monitoring of heart rate, respiratory rate, and oxygen saturation (SaO2). Computed tomography (CT) was used to determine the route of percutaneous insertion of the radiofrequency needle. After sterilization of the puncture site, 0.5% lidocaine was administered for local anesthesia. A 20-G radiofrequency needle (14.5-cm long, and with a 10-mm active tip; Baylis Medical Company, Montreal, Canada) was inserted and advanced slowly toward the foramen ovale along the designated path till the needle tip reached the predefined depth. CT was repeated to confirm the correct location of the needle tip. After the needle tip had advanced no more than 1.0 cm past the foramen ovale, electrical stimulation was performed. Sensory testing (50 Hz), 0.1–0.3 V is used to confirm that paresthesia covered the whole affected area. In case of unsatisfactory coverage, the place of the needle tip was adjusted. Because with HL-PRF the temperature may rise >42°C, motor stimulation (2 Hz) 0.5 V is performed to ensure that no damage occurs to the motor innervation when the V3 division is targeted (Fig. 2).

PRF treatment was performed using the Pain Management Generator (PM-230; Baylis Medical Company, Montreal, Canada). In the HL-PRF group, treatment was initiated with the following parameters: 42°C, 2 Hz, 20 msec, and 900 sec duration. The initial voltage output of 40 V was gradually increased until the patient could not tolerate the abnormal sensation (i.e., burning pain). The maximal voltage output ranged from 60 V to 100 V. Treatment was terminated after 900 sec. In the S-PRF group, treatment was with the following settings: 42°C, 2 Hz, 20 msec, and 120 sec duration. Three cycles were administered in auto-standard mode (Fig. 3).

Blinding
All PRF procedures were performed by the same investigator (Dr. 1). The follow-up assessments were performed by two other investigators (Dr. 2 and Dr. 3) who were blinded to the PRF mode. The PRF instrument was operated by a nurse who did not participate in any other therapeutic or follow-up activities or trial discussions.

Post-PRF Drugs
After PRF, patients received pregabalin according to the pain severity. The initial dose was 50 mg every 12 hours. The dose was gradually increased if VAS scores were ≥3 or if the frequency of acute pain flares was >6 per day. Other medications were avoided.

Primary Outcome
Visual Analog Scale
The VAS scores were recorded before treatment and on the mornings of days 3, 7, and 14, and months 1, 3, and 6 after treatment.
Secondary Outcome

SF-36 Score

The SF-36 (21,22) was used to assess the health of patients. The questionnaire, which can be completed in just 6–9 min, assesses nearly all conceptual domains of the substantially longer generic self-administered questionnaires that have been used in other studies (23). The scores for each domain—bodily pain, general health, mental health, physical function, physical role, role-emotional, social function, and vitality—were recorded before treatment and on day 7 and months 1, 3, and 6 after treatment.

Mean Dose of Rescue Medication

The mean doses of pregabalin required on days 0, 3, 7, 14, and 28 after treatment were calculated in both groups.

Adverse Events

Occurrence of adverse events (i.e., bleeding at puncture site, infection, new cranial nerve injury symptoms of hypoesthesia of face or weakness of masseter muscle, intracranial hemorrhage, cerebrospinal fluid leak) was recorded on days 1, 7, and 14 after treatment.

Statistical Analysis

Sample size calculation was based on the findings of our previous study (19), where the effective rate of semilunar ganglion neuromodulation was 90% in the test group vs. 52% in the control group. To detect a difference of this magnitude with a power of 0.8 and type-I error of 0.05, we estimated that at least 28 patients would be required per group. To allow for a potential dropout rate of 5%, we decided to enroll 60 patients per group.

Normality of distribution of continuous variables was confirmed by the Kolmogorov–Smirnov test. Continuous variables were summarized as means ± standard deviation. Mean values at different time points were compared using the repeated-measures analysis of variance. Categorical variables were summarized as percentages and compared using the Fisher exact test. Statistical analysis was performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). Statistical significance was at $p < 0.05$.

RESULTS

Patient Demographics

Demographic characteristics were comparable between the HL-PRF group and the S-PRF group (Table 1). While one patient in the HL-PRF group died within six months of enrollment and two patients each in the HL-PRF group and the S-PRF group dropped out during follow-ups; these five patients were not included in the final analysis (Fig. 1).

Visual Analog Scale

The pretreatment mean VAS scores were comparable in the two groups. The post-treatment VAS scores were significantly lower than baseline scores in both groups at all time points ($p < 0.001$; Fig. 4). The mean VAS scores were significantly lower in the HL-PRF group than in the S-PRF group at days 4 and 7 and months 3 and 6 after treatment ($p < 0.05$; Fig. 4 and Table 2).

SF-36

The pretreatment SF-36 scores were comparable in the two groups. The scores for each domain (bodily pain, general health, mental health, physical function, physical role, role-emotional, social function, and vitality) improved significantly from baseline level at all time points after treatment in both groups ($p < 0.001$; Fig. 5 and Table 3).
Bodily Pain
The scores for bodily pain indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at six months after treatment ($p < 0.05$; Fig. 5a and Table 3).

General Health
The scores for general health indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at seven days and at six months after treatment ($p < 0.05$; Fig. 5b and Table 3).

Mental Health
The scores for mental health indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at three months after treatment ($p < 0.05$; Fig. 5c and Table 3).

Physical Function
The scores for physical function indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at one and six months after treatment ($p < 0.05$; Fig. 5d and Table 3).

Physical Role
The scores for physical role indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at three months after treatment ($p < 0.05$; Fig. 5e and Table 3).

Social Function
The scores for social function indicated significantly greater improvement in the HL-PRF group than in the S-PRF group at six months after treatment ($p < 0.05$; Fig. 5g and Table 3).

Rescue Drug Dosage
The mean doses of the rescue drug (pregabalin) were significantly lower in the HL-PRF group than in the S-PRF group on days 3, 14, and 28 after treatment ($p < 0.05$; Fig. 6 and Table 4).

Adverse Events
No patient had bleeding at the puncture site, infection, new cranial nerve injury symptoms of hypoesthesia of face or weakness of masseter muscle, intracranial hemorrhage, or other serious adverse events after PRF treatment. Ecchymoses formed on the face in 7 patients in the S-PRF group and 11 patients in the HL-PRF group but subsided rapidly in all cases.

DISCUSSION
In this study, PRF neuromodulation of the gasserian ganglion effectively relieved trigeminal PHN in elderly patients and significantly improved their quality of life. The analgesia was better and the incidence of adverse events was lower with HL-PRF than with the standard-mode PRF. No serious adverse events occurred with either mode.

PHN is a severe neuropathic pain that occurs following herpes zoster. Immune system dysfunction due to aging, infection, malignant disease, or other conditions results in reactivation of latent virus and causes severe inflammation in the posterior root spinal neurons or cranial nerve ganglia. Massive viral replication can

---

**Table 1.** Baseline Characteristics of the Participants (Mean ± Standard Deviation).

| Patients | S-PRF group ($N = 58$) | HL-PRF group ($N = 57$) |
|----------|------------------------|-------------------------|
| Age (years) | 69.96 ± 13.66 | 70.54 ± 14.02 |
| Female/male, N | 35/23 | 36/21 |
| Weight (kg) | 68.19 ± 10.67 | 67.64 ± 12.47 |
| Disease duration (days) | 65.14 ± 18.53 | 67.28 ± 19.64 |
| Average pain scores | 7.61 ± 2.49 | 7.39 ± 2.43 |
| HZ distribution, N (I/II/III branch) | 15/18/25 | 12/17/28 |
| Presence of ocular complications, N | 4 | 5 |

HL-PRF, high-voltage, long-duration PRF; S-PRF, standard PRF.

---

**Table 2.** Changes of VAS Scores Before and After Treatment.

| VAS scores | S-PRF group ($N = 58$) | HL-PRF group ($N = 57$) |
|------------|------------------------|-------------------------|
| Baseline | 7.35 ± 1.93 | 7.39 ± 2.08 |
| 3 days after PRF | 3.39 ± 1.14* | 3.02 ± 0.85* |
| 7 days after PRF | 3.24 ± 1.00* | 2.34 ± 0.64* |
| 14 days after PRF | 2.94 ± 1.02* | 2.10 ± 0.45* |
| 1 month after PRF | 2.88 ± 0.96* | 2.55 ± 0.61* |
| 3 months after PRF | 3.05 ± 0.89* | 2.12 ± 0.54* |
| 6 months after PRF | 3.21 ± 1.01* | 1.97 ± 0.65* |

HL-PRF, high-voltage, long-duration PRF; PRF, pulsed radiofrequency; S-PRF, standard PRF; VAS, visual analog scale. *$p < 0.001$ indicates pre VAS vs. post VAS. †$p < 0.05$ indicates high-voltage, long-duration PRF (HL-PRF) group vs. standard PRF (S-PRF) group.

---

**Table 3.** Changes of VAS Scores Before and After Treatment.

| VAS scores | S-PRF group ($N = 58$) | HL-PRF group ($N = 57$) |
|------------|------------------------|-------------------------|
| Baseline | 7.35 ± 1.93 | 7.39 ± 2.08 |
| 3 days after PRF | 3.39 ± 1.14* | 3.02 ± 0.85* |
| 7 days after PRF | 3.24 ± 1.00* | 2.34 ± 0.64* |
| 14 days after PRF | 2.94 ± 1.02* | 2.10 ± 0.45* |
| 1 month after PRF | 2.88 ± 0.96* | 2.55 ± 0.61* |
| 3 months after PRF | 3.05 ± 0.89* | 2.12 ± 0.54* |
| 6 months after PRF | 3.21 ± 1.01* | 1.97 ± 0.65* |

HL-PRF, high-voltage, long-duration PRF; PRF, pulsed radiofrequency; S-PRF, standard PRF; VAS, visual analog scale. *$p < 0.001$ indicates pre VAS vs. post VAS. †$p < 0.05$ indicates HL-PRF group vs. S-PRF group.
cause cell dehydration and apoptosis, chronic inflammatory cell infiltration, and other complicated pathological changes in the primary sensory neurons (24). Patients typically present with spontaneous pain, allodynia, and hyperalgesia in the distribution of the affected nerve (25). Because the etiology and mechanism of PHN remain unclear, there is still no effective treatment (26–29).

The trigeminal nerve is the main orofacial sensory nerve. Activation and replication of latent herpes zoster virus in the gasserian ganglion result in PHN (30). In the elderly, the risk of developing PHN is higher after trigeminal herpes zoster than after a spinal nerve herpes zoster (31); pain relief with drugs and other therapies is also less likely. Therefore, the

Figure 5. (a–h) Significantly improved mean SF-36 scores after treatment. *p < 0.001 indicates pre scores of SF-36 vs. post scores. #p < 0.05 indicates high-voltage, long-duration PRF (HL-PRF) group vs. standard PRF (S-PRF) group.
PHN is very essential. The need for an intervention to prevent progression to trigeminal PHN is very essential.

With a discontinuous pulse current (20 msec, 2 Hz), PRF is a minimally invasive treatment (32) that could provide long-term analgesia (33). Many clinical and experimental studies have shown that PRF can control neuropathic pain (34). The gasserian ganglion plays a critical role in expressing various signaling molecules that modulate peripheral and central sensitization. Arici et al. have previously shown that PRF neuromodulation of the gasserian ganglion can achieve good analgesia (35,36); therefore, we chose the gasserian ganglion as the therapeutic target in this study.

In this study, other than voltage and time settings, the parameters were the same in the HL-PRF and S-PRF groups. Patients in both groups obtained significant pain relief and improvement of life quality. However, the improvement was greater in the HL-PRF. Elzieta et al. (37) have previously shown that increasing the magnitude of the electric field through high voltage might be more effective for pain relief.

We recognize several limitations in this study. First, this was a single-center study with a small sample. Second, the patients were only followed up for six months after treatment.

### CONCLUSION

The HL-PRF mode for gasserian ganglion neuromodulation may be more effective than standard-mode PRF for reducing the incidence and severity of trigeminal PHN in elderly patients with acute or recent trigeminal herpes zoster. Both modes appear to be comparably safe.

### Acknowledgements

We would like to thank all the patients, doctors, and nurses involved in the current study.

### Authorship Statement

Cheng-Fu Wan was responsible for clinical experiment design, follow-up, data collection and analysis, and manuscript writing; and Tao Song was responsible for the clinical experiment design and manuscript review. Both authors approved the final version of the manuscript.

---

**Table 3. Changes of Qualities of Life Scores Before and After Treatment.**

|                | Baseline | Seven days | One month | Three months | Six months |
|----------------|----------|------------|-----------|--------------|------------|
| Body pain      | S-PRF group | 36.06 ± 6.94 | 70.21 ± 12.29<sup>*</sup> | 73.41 ± 7.54<sup>*</sup> | 75.99 ± 9.07<sup>*</sup> | 74.37 ± 8.90<sup>*</sup> |
|                | HL-PRF group | 36.84 ± 6.17 | 75.67 ± 10.39<sup>†</sup> | 81.77 ± 7.54<sup>†</sup> | 83.79 ± 6.69<sup>†</sup> | 88.89 ± 8.81<sup>††</sup> |
| General health | S-PRF group | 40.69 ± 8.14 | 64.10 ± 8.61<sup>†</sup> | 76.80 ± 9.54<sup>†</sup> | 87.00 ± 7.88<sup>†</sup> | 89.97 ± 9.59<sup>††</sup> |
|                | HL-PRF group | 41.29 ± 8.60 | 74.98 ± 9.24<sup>††</sup> | 80.32 ± 8.35<sup>††</sup> | 70.91 ± 6.27<sup>†</sup> | 73.21 ± 5.90<sup>†</sup> |
| Mental health  | S-PRF group | 38.92 ± 3.94 | 67.60 ± 5.29<sup>†</sup> | 69.39 ± 4.54<sup>†</sup> | 78.79 ± 7.69<sup>†</sup> | 80.29 ± 8.89<sup>†</sup> |
|                | HL-PRF group | 37.99 ± 4.17 | 70.98 ± 9.24<sup>†</sup> | 76.74 ± 8.94<sup>†</sup> | 78.71 ± 7.97<sup>†</sup> | 80.84 ± 9.11<sup>†</sup> |
| Physical function | S-PRF group | 34.76 ± 6.09 | 64.75 ± 8.98<sup>†</sup> | 65.46 ± 7.56<sup>†</sup> | 69.38 ± 8.27<sup>†</sup> | 70.84 ± 9.11<sup>†</sup> |
|                | HL-PRF group | 34.24 ± 7.00 | 71.01 ± 9.54<sup>†</sup> | 78.98 ± 8.54<sup>††</sup> | 72.61 ± 7.97<sup>†</sup> | 82.48 ± 8.89<sup>††</sup> |
| Physical role  | S-PRF group | 41.29 ± 6.87 | 61.21 ± 6.98<sup>†</sup> | 69.59 ± 8.84<sup>†</sup> | 66.23 ± 6.27<sup>†</sup> | 73.43 ± 7.50<sup>†</sup> |
|                | HL-PRF group | 42.49 ± 6.17 | 69.95 ± 8.90<sup>†</sup> | 75.29 ± 7.54<sup>†</sup> | 78.20 ± 9.97<sup>†</sup> | 79.74 ± 8.85<sup>†</sup> |
| Role-emotional | S-PRF group | 43.31 ± 4.96 | 63.80 ± 7.01<sup>†</sup> | 66.39 ± 8.34<sup>†</sup> | 71.26 ± 8.27<sup>†</sup> | 74.69 ± 9.02<sup>†</sup> |
|                | HL-PRF group | 43.91 ± 4.55 | 65.98 ± 6.92<sup>†</sup> | 70.74 ± 9.94<sup>†</sup> | 78.79 ± 8.67<sup>†</sup> | 77.27 ± 10.21<sup>†</sup> |
| Social function | S-PRF group | 39.61 ± 3.65 | 66.45 ± 6.02<sup>†</sup> | 74.08 ± 8.45<sup>†</sup> | 75.05 ± 7.87<sup>†</sup> | 75.69 ± 8.23<sup>†</sup> |
|                | HL-PRF group | 38.81 ± 4.01 | 70.98 ± 7.39<sup>†</sup> | 78.50 ± 6.94<sup>†</sup> | 80.70 ± 8.65<sup>†</sup> | 83.45 ± 6.89<sup>††</sup> |
| Vitality       | S-PRF group | 41.55 ± 5.87 | 65.21 ± 8.98<sup>†</sup> | 69.99 ± 7.54<sup>†</sup> | 73.48 ± 9.27<sup>†</sup> | 78.18 ± 8.90<sup>†</sup> |
|                | HL-PRF group | 42.19 ± 6.17 | 69.64 ± 9.00<sup>†</sup> | 74.29 ± 10.54<sup>†</sup> | 79.20 ± 8.07<sup>†</sup> | 80.24 ± 7.29<sup>†</sup> |

HL-PRF, high-voltage, long-duration PRF; PRF, pulsed radiofrequency; S-PRF, standard PRF. *p < 0.001 indicates pre pregabalin dosage vs. post dosage. †p < 0.05 indicates high-voltage, long-duration PRF (HL-PRF) group vs. standard PRF (S-PRF) group.

---

**Table 4. Changes of Pregabalin Doses Before and After Treatment.**

|                  | S-PRF group (N = 58) | HL-PRF group (N = 57) |
|------------------|----------------------|------------------------|
| 0 day after PRF  | 145.07 ± 28.57       | 131.30 ± 32.53        |
| 3 days after PRF | 102.51 ± 32.31<sup>†</sup> | 72.47 ± 38.24<sup>††</sup> |
| 7 days after PRF | 85.44 ± 29.53<sup>†</sup> | 69.25 ± 29.55<sup>†</sup> |
| 14 days after PRF| 86.56 ± 30.42<sup>†</sup> | 58.16 ± 23.13<sup>††</sup> |
| 28 days after PRF| 80.42 ± 10.26<sup>†</sup> | 50.99 ± 25.43<sup>†</sup> |

HL-PRF, high-voltage, long-duration PRF; PRF, pulsed radiofrequency; S-PRF, standard PRF. *p < 0.001 indicates pre pregabalin dosage vs. post dosage. †p < 0.05 indicates HL-PRF group vs. S-PRF group.

---

**Figure 6.** Significantly decreased mean dosages of pregabalin after treatment. *p < 0.001 indicates pre pregabalin dosage vs. post dosage. †p < 0.05 indicates high-voltage, long-duration PRF (HL-PRF) group vs. standard PRF (S-PRF) group.
REFERENCES

1. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009;84:274–280.

2. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010;48:52–57.

3. Fasbender J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2011;83:1432–1437.

4. Schlereth T, Heiland A, Breimhorst M et al. Association between pain, central sensitization and anxiety in postherpetic neuralgia. Eur J Pain 2015;19:193–201.

5. Johnson RW, Rice ASC. Clinical practice. Postherpetic neuralgia. N Engl J Med 2011;364:1135–1142.

6. Devor M. Rethinking the causes of pain in herpes zoster and postherpetic neuralgia. Pain Rep 2018;3:e702.

7. Shannon HJ, Anderson J, Damle JS. Evidence for interventional procedures as an adjunct therapy in the treatment of shingles pain. Adv Skin Wound Care 2012;25:276–284.

8. Forbes HU, Thomas S, Smeeth L et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016;157:50–54.

9. Kawai K, Rampakakis E, Tsai TF et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. Int J Infect Dis 2015;34:126–131.

10. Bouhassira D, Chasseray O, Gallaj J et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012;153:342–349.

11. Doth AH, Hansson P, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Mayo Clin Proc 2011;86:1147–1153.

12. Doth AH, Hansen P, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Mayo Clin Proc 2011;86:1147–1153.

13. van Boxem K, Houtoo M, Van Zundert J, Pattijn J, van Kleef M, Joosten EA. Pulsed radiofrequency: a review of the basic science as applied to the pathophysiology of radicular pain: a call for clinical translation. Reg Anesth Pain Med 2014;39:149–159.

14. Cosman ER Jr, Cosman ER Jr. Electric and thermal field effects in tissue around radiofrequency electrodes. Pain Med 2005;6:405–424.

15. Ke MD, Yinghui F, Yi J et al. Efficacy of pulsed radiofrequency in the treatment of thoracic postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial. Pain Physician 2014;16:15–25.

16. Kim ED, Lee Y, Park HJ. Comparison of efficacy of continuous epidual block and pulsed radiofrequency to the dorsal root ganglion for management of pain persisting beyond the acute phase of herpes zoster. PLoS One 2017;12:e0183559.

17. Steven P, Cohen BLP, Fulton L et al. Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness. Pain Physician 2015;18:2585–2594.

18. Wan CF, Liu Y, Dong Ds et al. Bipolar high-voltage, long-duration pulsed radiofrequency improves pain relief in postherpetic neuralgia. Pain Physician 2016;19: E721–E728.

19. Wan CF, Dong D, Song T. High-voltage, long-duration pulsed radiofrequency on gasserian ganglion improves acute/subacute zoster-related trigeminal neuralgia: a randomized, double-blinded, controlled trial. Pain Physician 2019;22:361–368.

20. Charlton E. Ethical guidelines for pain research in humans. Committee on Ethical issues of the International Association for the Study of Pain. Pain 1995;63: 277–278.

21. Dong DS, Yu X, Wan CF et al. Efficacy of short-term spinal cord stimulation in acute/subacute zoster-related pain: a retrospective study. Pain Physician 2017;20: E633–E645.

22. Keller SD, Majkut T, Kosinski M, Ware JE Jr. Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview. Med Care 1999; 37:S51–S59.

23. Sacks GM, Umret need in the treatment of postherpetic neuralgia. Am J Manag Care 2013;19:5207–5213.

24. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14: 162–173.

25. Kumar V, Krone K, Mathieu A. Neuropathic and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med 2004;29:454–461.

26. Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007;57:S136–S142.

27. Stinson C, Deng M, Yee MB, Bellinger LL, Kinchington PR, Kramer PR. Sex differences underlining orofacial varicella zoster associated pain in rats. BMC Neurol 2017;17:95.

28. Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002;46:834–839.

29. Shi Y, Wu W. Treatment of neuropathic pain using pulsed radiofrequency: a meta-analysis. Pain Physician 2016;19:429–444.

30. Perret DM, Kim D, Li KW et al. Application of pulsed radiofrequency currents to rat dorsal root ganglia modulates nerve injury-induced tactile allodynia. Anesth Analg 2011;113:610–616.

31. Arini S, Bilir A, Cosman ER, Cosman ER Jr. Ultrastructural changes in axons following exposure to pulsed radiofrequency fields. Pain Pract 2009;9:407–417.

32. Anci T, Kurcaloglu M, Kyle C, Erhan E. Radiofrequency thermocoagulation combined with pulsed radiofrequency for gasserian ganglion blockade. Agri 2018;30:179–182.

33. Ding Y, Hong T, Li H, Yao P, Zhao G. Efficacy of CT guided pulsed radiofrequency treatment for trigeminal postherpetic neuralgia. Front Neurosci 2019;13:708.

34. Ewertowska E, Mercadal B, Muñoz V, Ivorra A, Trujillo M, Berjano E. Effect of applied voltage, duration and repetition frequency of RF pulses for pain relief on temperature spikes and electrical field: a computer modelling study. Int J Hyperthermia 2017;34:112–121.

COMMENTS

The management of postherpetic neuralgia is often difficult, because of minimal effect or intolerable side effects of pharmacological treatment. Herpes infection in the trigeminal nerves can evolve into postherpetic trigeminal neuralgia.

Conventional radiofrequency (RF) treatment of the Gasserian ganglion reduces pain, but may also induce analgesia dolorosa, a serious complication. Pulsed radiofrequency (PRF) treatment was compared to RF in a randomized controlled trial (1). The pain was reduced in both groups of 20 patients each, but the effect of PRF waned off 3 months after the intervention. In the RF group one patient developed anesthesia dolorosa, in the PRF group no side effects were reported.

In a search to combine the efficacy of RF with the safety of PRF, the effect of combining PRF with continuous radiofrequency was assessed in a trial that randomly allocated patients to short continuous radiofrequency (PRF) treatment was compared to RF in a randomized controlled trial (1). The pain was reduced in both groups of 20 patients each, but the effect of PRF waned off 3 months after the intervention. In the RF group one patient developed anesthesia dolorosa, in the PRF group no side effects were reported.

The use of high voltage PRF (HV PRF) was reported in a retrospective study (3) and an RCT (4) that found that PRF of the Gasserian resulted in a longer lasting effect than PRF at low voltage without compromising the safety. The authors of the current study published the comparative results of HV PRF with sham intervention. Patients in the HV PRF group had a significant pain reduction lasting up to 6 months (5).

No serious adverse events were reported with HV PRF.

The voltage used depends on the patients, tolerance, therefore we see a wide variation in voltages, which makes it difficult to interpret. Moreover, it is not clear whether HV PRF induces tissue damage.
Up till now the results obtained in a difficult to treat population are encouraging and further research should be performed.

Jan Van Zundert
Genk/Lanaken, Belgium

References
1. Erdine S, Yucel A, Cimen A, Aydin S, Sav A, Bilir A. Effects of pulsed versus conventional radiofrequency current on rabbit dorsal root ganglion morphology. *Eur J Pain*. 2005;9(3):251–256.
2. Li X, Ni J, Yang L, et al. A prospective study of Gasserian ganglion pulsed radiofrequency combined with continuous radiofrequency for the treatment of trigeminal neuralgia. *J Clin Neurosci*. 2012;19(6):824–828.
3. Luo F, Meng L, Wang T, Yu X, Shen Y, Ji N. Pulsed radiofrequency treatment for idiopathic trigeminal neuralgia: a retrospective analysis of the causes for ineffective pain relief. *Eur J Pain*. 2013;17(8):1189–1192.
4. Fang L, Tao W, Jingjing L, Nan J. Comparison of High–voltage–with Standard–voltage Pulsed Radiofrequency of Gasserian Ganglion in the Treatment of Idiopathic Trigeminal Neuralgia. *Pain Pract*. 2015;15(7):595–603.
5. Wan C, Dong DS, Song T. High–voltage, long–duration pulsed radiofrequency on gasserian ganglion improves acute/subacute zoster–related trigeminal neuralgia: A randomized, double–blinded, controlled trial. *Pain Physician*. 2019;22(4):361–368.